P102 - Topic: AS06-Prognosis/AS06b-Predictive factors of response to treatment: NOVEL PREDICTIVE INDICATORS IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC NEOPLASMS (HR-MDS) TREATED WITH 5-AZACYTIDINE: CUMULATIVE DATA FROM THE HELLENIC MDS STUDY GROUP

Autor: Kotsianidis, I., Hatzimichael, E., Pappa, V., Galanopoulos, A., Kourakli, A., Diamantopoulos, P., Papageorgiou, S., Liapis, K., Papadopoulos, V., Papoutselis, M., Bouchla, A., Georgoulis, V., Vassilakopoulos, T., Solomou, E., Dimou, M., Vassilopoulos, G., Vardi, A., Papaioannou, M., Pontikoglou, C., Anagnostopoulos, A., Panayiotidis, P., Kontopidou, F., Harchalakis, N., Adamopoulos, N., Ximeri, M., Zikos, P., Megalakaki, A., Repousis, P., Kotsopoulou, M., Dryllis, G., Tsoukanas, D., Kyrtsonis, M.-C., Poulakidas, E., Bouronikou, E., Delimpasis, S., Mparmparousi, D., Papadaki, H., Vyniou, N.A., Symeonidis, A.

Publikováno v: In Leukemia Research May 2023 128 Supplement

Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes

Autor: Papageorgiou, S.G. Kotsianidis, I. Bouchla, A. Symeonidis, A. Galanopoulos, A. Viniou, N.-A. Hatzimichael, E. Vassilakopoulos, T.P. Gogos, D. Megalakaki, A. Zikos, P. Diamantopoulos, P. Kourakli, A. Giannoulia, P. Papoutselis, M. Poulakidas, E. Arapaki, M. Vardi, A. Anagnostopoulos, A. Mparmparousi, D. Papaioannou, M. Bouronikou, E. Dimou, M. Papadaki, H. Panayiotidis, P. Pappa, V.

Background: 5-azacytidine (5-AZA) improves survival of patients with higher-risk myelodysplastic syndromes (MDSs) and oligoblastic acute myeloid leukemia (AML); however, predictive factors for response and outcome have not been consistently studied.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::2f1346cbba3a388fdd0c272409f84d91
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3104904

The outcome of patients with high-risk MDS achieving stable disease after treatment with 5-azacytidine: A retrospective analysis of the Hellenic (Greek) MDS Study Group

Autor: Papageorgiou, S.G. Kontos, C.K. Kotsianidis, I. Vasilatou, D. Symeonidis, A. Galanopoulos, A. Bouchla, A. Hatzimichael, E. Repousis, P. Zikos, P. Viniou, N.-A. Poulakidas, E. Vassilakopoulos, T.P. Diamantopoulos, P. Diamantopoulos, M.A. Mparmparousi, D. Bouronikou, E. Papadaki, H. Panayiotidis, P. Pappa, V.

The demethylating factor 5-azacytidine (5-AZA) improves survival in intermediate-2 and high-risk myelodysplastic syndrome (MDS) patients [according to the International Prognostic Score System (IPSS)] responding to treatment. However, the outcome of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::224499392c34225e5bdf35d20b7ae8bd
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3086564

Body mass index and relative dose intensity does not affect the response and outcome of high-risk MDS patients treated with azacytidine. Results from the Hellenic (Greek) MDS study group

Autor: Papageorgiou, S.G. Kotsianidis, I. Kontos, C.K. Symeonidis, A. Galanopoulos, A. Hatzimichael, E. Poulakidas, E. Diamantopoulos, P. Vassilakopoulos, T.P. Zikos, P. Papadaki, H. Bouronikou, E. Panayiotidis, P. Viniou, N.-A. Pappa, V.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::8685838cc84852a40edd9b7358bee096
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3087480

Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes.

Autor: Papageorgiou SG; Consultant of Hematology, Second Department of Internal Medicine and Research Unit, University General Hospital 'Attikon', 1 Rimini St., Haidari, Athens, 12462, Greece., Kotsianidis I; Department of Hematology, Democritus University of Thrace Medical School, University Hospital of Alexandroupolis, Alexandroupolis, Greece., Bouchla A; Second Department of Internal Medicine and Research Unit, University General Hospital 'Attikon', Haidari, Athens, Greece., Symeonidis A; The Hellenic (Greek) MDS Study Group, Greece., Galanopoulos A; The Hellenic (Greek) MDS Study Group, Greece., Viniou NA; The Hellenic (Greek) MDS Study Group, Greece., Hatzimichael E; University Hospital of Ioannina, Ioannina, Greece., Vassilakopoulos TP; Department of Hematology, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece., Gogos D; General Hospital 'Bostanio' Mytilini, Greece., Megalakaki A; Department of Hematology, 'Metaxa' Piraeus Cancer Hospital, Piraeus, Greece., Zikos P; General Hospital of Patras 'Agios Andreas', Patras, Greece., Diamantopoulos P; Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece., Kourakli A; General University Hospital of Patras, Rio Patron, Patras, Greece., Giannoulia P; Department of Hematology, 'Evangelismos' Hospital, Athens, Greece., Papoutselis M; Department of Hematology, Democritus University of Thrace Medical School, University Hospital of Alexandroupolis, Alexandroupolis, Greece., Poulakidas E; '401' Army General Hospital of Athens, Mesogeion and Kanellopoulou 1, Athens, Greece., Arapaki M; Department of Hematology, National and Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece., Vardi A; Hematology Department, General Hospital of Thessaloniki 'George Papanikolaou', Thessaloniki, Greece., Anagnostopoulos A; Hematology Department, General Hospital of Thessaloniki 'George Papanikolaou', Thessaloniki, Greece., Mparmparousi D; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Papaioannou M; Hematology Department, University General Hospital of Thessaloniki AHEPA, Thessaloniki, Greece., Bouronikou E; University General Hospital of Larissa, Mezourlo, Larissa, Greece., Dimou M; First Propaedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece., Papadaki H; University General Hospital of Heraklion, Voutes, Heraklion, Greece., Panayiotidis P; First Propaedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece., Pappa V; Second Department of Internal Medicine and Research Unit, University General Hospital 'Attikon', Haidari, Athens, Greece.

Publikováno v: Therapeutic advances in hematology [Ther Adv Hematol] 2020 Dec 08; Vol. 11, pp. 2040620720966121. Date of Electronic Publication: 2020 Dec 08 (Print Publication: 2020).